MedVellum
MedVellum
Back to Library
Psychiatry
Emergency Medicine
Gastroenterology
EMERGENCY

Alcohol Dependence & Withdrawal

High EvidenceUpdated: 2025-12-24

On This Page

Red Flags

  • Delirium tremens (confusion, seizures, hallucinations)
  • Wernicke's encephalopathy (confusion, ataxia, ophthalmoplegia)
  • Seizures without prior history
  • Hypoglycaemia or electrolyte disturbance
  • Aspiration or respiratory depression
Overview

Alcohol Dependence & Withdrawal

1. Clinical Overview

Summary

Alcohol dependence (alcohol use disorder, AUD) is a chronic relapsing condition characterised by compulsive alcohol use, loss of control over intake, and a negative emotional state when not drinking. Alcohol withdrawal syndrome (AWS) occurs when chronic heavy drinkers suddenly reduce or stop drinking, ranging from mild tremor and anxiety to life-threatening delirium tremens and seizures. Management of AWS requires careful assessment, thiamine replacement, and benzodiazepine-based detoxification. Long-term recovery requires pharmacotherapy, psychological support, and engagement with mutual aid groups.

Key Facts

  • Prevalence: 5-10% of adults meet criteria for AUD; 20% of hospital inpatients
  • Mortality: Delirium tremens has 5-15% mortality if untreated
  • Wernicke's encephalopathy: Caused by thiamine (B1) deficiency; preventable with IV thiamine
  • Withdrawal timeline: Tremor 6-12h → Seizures 12-48h → DTs 48-72h
  • Key management: Thiamine BEFORE glucose; symptom-triggered benzodiazepines
  • Prevention of relapse: Acamprosate, naltrexone, disulfiram, psychosocial support

Clinical Pearls

Thiamine Before Glucose: Always give IV thiamine before any glucose-containing fluids in at-risk patients. Glucose administration can precipitate or worsen Wernicke's encephalopathy.

The 48-72 Hour Window: Delirium tremens typically develops 48-72 hours after the last drink. Patients who appear stable at 24 hours may still deteriorate — maintain vigilance.

The Concealed Drinker: Hospital inpatients often underreport alcohol use. Any patient with unexplained tremor, confusion, or agitation 2-3 days into admission should be assessed for AWS.

Why This Matters Clinically

Alcohol withdrawal is common in hospital settings and frequently unrecognised until complications occur. Delirium tremens carries significant mortality and morbidity. Early recognition and treatment prevent seizures, aspiration, and death. Wernicke's encephalopathy is preventable but irreversible once Korsakoff's syndrome develops.


2. Epidemiology

Incidence & Prevalence

  • AUD prevalence: 5-10% of adults in UK
  • Hospital inpatients: 20% drink at hazardous levels
  • AWS incidence: 50% of alcohol-dependent patients experience withdrawal
  • DT incidence: 3-5% of those with withdrawal
  • Wernicke's encephalopathy: 0.4-2.8% of dependent drinkers; often underdiagnosed

Demographics

FactorDetails
AgePeak 18-29 years; chronic dependence in older adults
SexMale 2x more likely; women progress faster
SocioeconomicAll groups affected; higher rates in deprivation
Psychiatric comorbidity50% have concurrent mental health disorder

Risk Factors for Severe Withdrawal

Predicting Severe AWS/DT:

  • Previous DT or withdrawal seizures
  • Prolonged heavy drinking (greater than 8 units/day)
  • Previous complicated withdrawal
  • Concurrent medical illness
  • Age greater than 40
Risk FactorImpact
Previous DT5x risk of recurrence
Previous seizures3x risk
High alcohol intakeDose-dependent
Concurrent illnessIncreases severity

3. Pathophysiology

Mechanism

Step 1: Chronic Alcohol Exposure

  • Alcohol enhances inhibitory GABA-A receptor activity
  • Alcohol inhibits excitatory NMDA glutamate receptors
  • Brain adapts: downregulation of GABA receptors, upregulation of NMDA receptors

Step 2: Withdrawal State

  • Sudden cessation removes inhibitory effect
  • Relative excess of excitatory glutamatergic activity
  • Sympathetic nervous system activation
  • Neuronal hyperexcitability

Step 3: Clinical Manifestations

  • Mild: Tremor, anxiety, insomnia (6-12 hours)
  • Moderate: Hallucinations, hypertension, tachycardia (12-24 hours)
  • Severe: Seizures, delirium tremens (24-72 hours)

Step 4: Wernicke's Encephalopathy (Separate Pathway)

  • Thiamine (B1) deficiency from malnutrition and malabsorption
  • Impaired glucose metabolism in vulnerable brain regions
  • Damage to mammillary bodies, medial thalamus, brainstem
  • Triad: Confusion, ataxia, ophthalmoplegia

Classification

Alcohol Use Disorder (DSM-5):

  • Mild: 2-3 criteria
  • Moderate: 4-5 criteria
  • Severe: 6+ criteria

Withdrawal Severity:

StageTimelineFeatures
Mild6-12 hoursTremor, anxiety, insomnia, nausea, sweating
Moderate12-24 hoursTachycardia, hypertension, fever, hallucinations
Severe DT48-72 hoursDelirium, seizures, autonomic instability

4. Clinical Presentation

Symptoms

Alcohol Dependence:

Withdrawal Syndrome:

Delirium Tremens:

Wernicke's Encephalopathy Triad:

Signs

Red Flags

[!CAUTION] Red Flags — Urgent treatment required if:

  • Seizures (may be first presentation)
  • Delirium (confusion, hallucinations, agitation) — DT
  • Confusion + ataxia ± ophthalmoplegia — Wernicke's encephalopathy
  • Hyperthermia (temperature greater than 38.5°C)
  • Cardiovascular instability (severe hypertension or hypotension)

Strong desire or compulsion to drink
Common presentation.
Difficulty controlling drinking behaviour
Common presentation.
Increased tolerance
Common presentation.
Neglect of other activities
Common presentation.
Continued drinking despite harmful consequences
Common presentation.
Withdrawal symptoms on cessation
Common presentation.
5. Clinical Examination

Structured Approach

General:

  • Vital signs (HR, BP, temperature, RR)
  • Level of consciousness and orientation
  • Hydration status
  • Signs of chronic liver disease (jaundice, spider naevi, hepatomegaly)

Neurological:

  • Tremor assessment
  • Eye movements (nystagmus, ophthalmoplegia)
  • Gait (ataxia)
  • Reflexes (hyperreflexia in withdrawal)
  • Confusion/orientation (AMT, 4AT)

Cardiovascular:

  • Heart rate and rhythm
  • Blood pressure

Special Tests

TestTechniquePositive FindingPurpose
CIWA-ArStandardised assessment toolScore greater than 10 indicates need for treatmentGuide benzodiazepine dosing
CAGE Questionnaire4 questions2+ positive = likely dependenceScreening
AUDIT10-item questionnaireScore greater than 8 = hazardous drinkingComprehensive screening
SADQ20-item questionnaireScore indicates severityAssess dependence severity

6. Investigations

First-Line (Bedside)

  • Observations — HR, BP, temperature, RR
  • Blood glucose — Hypoglycaemia common
  • CIWA-Ar score — Guides treatment
  • Urinalysis — Exclude UTI as cause of confusion

Laboratory Tests

TestExpected FindingPurpose
FBCMacrocytosis (MCV greater than 100), anaemiaChronic alcohol effect
LFTsRaised GGT, AST:ALT greater than 2:1Liver damage
U&EsHypokalaemia, hypomagnesaemia, hyponatraemiaElectrolyte disturbance
ClottingProlonged PT/INR if liver failureLiver synthetic function
GlucoseMay be lowMalnutrition, impaired gluconeogenesis
Amylase/LipaseElevated if pancreatitisComplication screening
Blood alcohol levelMay still be elevated or zeroContextual information

Imaging

ModalityFindingsIndication
CT HeadExclude subdural haematoma, infarctIf focal neurology, fall, confusion
CXRAspiration pneumoniaIf respiratory symptoms
MRI BrainMammillary body changes (Wernicke's)If Wernicke's suspected and diagnostic uncertainty

7. Management

Management Algorithm

         ALCOHOL WITHDRAWAL SYNDROME
                     ↓
┌─────────────────────────────────────────┐
│        ASSESS SEVERITY (CIWA-Ar)        │
│  Vitals, orientation, tremor, sweating  │
└─────────────────────────────────────────┘
                     ↓
┌─────────────────────────────────────────┐
│         THIAMINE (PABRINEX)             │
│  IV Pabrinex BEFORE any glucose         │
│  1 pair TDS for 3-5 days (prophylaxis)  │
│  2 pairs TDS if Wernicke's suspected    │
└─────────────────────────────────────────┘
                     ↓
┌─────────────────────────────────────────┐
│         BENZODIAZEPINE REGIMEN          │
├─────────────────────────────────────────┤
│  CIWA-Ar <10: Monitor                   │
│  CIWA-Ar 10-15: Chlordiazepoxide PRN    │
│  CIWA-Ar >15: Symptom-triggered dosing  │
│  SEVERE DT: IV Diazepam or Lorazepam    │
└─────────────────────────────────────────┘
                     ↓
┌─────────────────────────────────────────┐
│         CORRECT ELECTROLYTES            │
│  K⁺, Mg²⁺, PO₄³⁻ as needed              │
└─────────────────────────────────────────┘
                     ↓
┌─────────────────────────────────────────┐
│         RELAPSE PREVENTION              │
│  Acamprosate, Naltrexone, Disulfiram    │
│  Psychological support, AA referral     │
└─────────────────────────────────────────┘

Acute/Emergency Management

Immediate Actions:

  1. Secure airway if reduced consciousness
  2. IV access, bloods including glucose
  3. IV Pabrinex (thiamine) — BEFORE glucose
  4. Benzodiazepines for withdrawal symptoms
  5. Correct electrolyte abnormalities
  6. Monitor with CIWA-Ar scoring

IV Thiamine Dosing:

  • Prophylaxis: Pabrinex 1 pair (1 x 10ml ampoule pair) TDS for 3-5 days
  • Wernicke's encephalopathy: Pabrinex 2 pairs TDS for minimum 5 days, then oral

Conservative Management

  • Quiet, well-lit room to minimise hallucinations
  • Reassurance and orientation
  • Hydration (oral preferred if tolerated)
  • Nutritional support

Medical Management

Benzodiazepines (Core Treatment):

DrugIndicationRegimen
ChlordiazepoxideFirst-line (oral)Reducing regimen: 30mg QDS → reduce by 20% daily over 5-7 days
DiazepamAlternative oral or IV10-20mg PRN or reducing regimen
LorazepamLiver failure (shorter acting)1-2mg IM/IV PRN

Symptom-Triggered Therapy:

  • Give chlordiazepoxide 10-20mg PRN when CIWA-Ar greater than 10
  • Reassess hourly
  • Reduces total benzodiazepine dose and treatment duration

Relapse Prevention:

DrugMechanismDoseNotes
AcamprosateGABA modulation, reduces craving666mg TDSFirst-line; not hepatotoxic
NaltrexoneOpioid antagonist, reduces reward50mg ODContraindicated if active hepatitis
DisulfiramAldehyde dehydrogenase inhibitor200mg ODCauses severe reaction with alcohol; requires motivation

Surgical Management

  • Not applicable

Disposition

  • Admit if: Moderate-severe withdrawal (CIWA greater than 15), history of DT/seizures, comorbid illness, unable to self-care
  • Discharge if: Mild withdrawal, stable community support, planned outpatient detox, motivated patient
  • Follow-up: Alcohol liaison service, community addiction services, GP for ongoing prescribing

8. Complications

Immediate

ComplicationIncidencePresentationManagement
Seizures3-7% of withdrawalGeneralised tonic-clonicLorazepam 4mg IV, increase benzodiazepines
Delirium tremens3-5%Confusion, hallucinations, autonomic instabilityHigh-dose benzodiazepines, ICU if severe
Wernicke's encephalopathy0.4-2.8%Confusion, ataxia, ophthalmoplegiaIV Pabrinex

Early (Days)

  • Aspiration pneumonia: From reduced consciousness, vomiting
  • Electrolyte disturbance: Hypokalaemia, hypomagnesaemia cause arrhythmias
  • Hypoglycaemia: Malnutrition, impaired gluconeogenesis

Late (Weeks-Months)

  • Korsakoff's syndrome: Irreversible amnestic syndrome (anterograde and retrograde amnesia, confabulation) — follows untreated Wernicke's
  • Relapse: 40-60% within first year
  • Chronic liver disease: Alcoholic hepatitis, cirrhosis

9. Prognosis & Outcomes

Natural History

  • Mild withdrawal: Self-limiting over 3-5 days
  • Severe withdrawal: Progresses to DT if untreated
  • Untreated DT: 5-15% mortality
  • Wernicke's: 17% mortality; 80% develop Korsakoff's if untreated

Outcomes with Treatment

VariableOutcome
Mortality with treatmentLess than 1% (DT)
Abstinence at 1 year (no pharmacotherapy)20-30%
Abstinence at 1 year (with pharmacotherapy)40-50%
Recovery from Wernicke's80% with prompt treatment

Prognostic Factors

Good Prognosis:

  • Motivation to change
  • Strong social support
  • Engagement with addiction services
  • No previous complicated withdrawal

Poor Prognosis:

  • Previous DT or seizures
  • Multiple relapses
  • Concurrent mental health disorder
  • Homelessness or lack of social support
  • Advanced liver disease

10. Evidence & Guidelines

Key Guidelines

  1. NICE CG115 (2011) — Alcohol-use disorders: diagnosis and management. NICE CG115
  2. NICE CG100 — Alcohol-use disorders: prevention.
  3. SIGN 74 — The management of harmful drinking and alcohol dependence in primary care.

Landmark Trials

COMBINE Study (2006) — Combining medications and behavioural interventions

  • 1383 patients randomised to naltrexone, acamprosate, behavioural intervention, combinations
  • Key finding: Naltrexone and behavioural intervention both effective; no added benefit of combining all
  • Clinical Impact: Supports pharmacotherapy plus psychosocial intervention

UKATT Trial (2005) — UK Alcohol Treatment Trial

  • 742 patients randomised to motivational enhancement therapy vs social behaviour network therapy
  • Key finding: Both equally effective; outcomes depend on engagement
  • Clinical Impact: Emphasises importance of any structured intervention

Evidence Strength

InterventionLevelKey Evidence
Benzodiazepines for withdrawal1aCochrane review
Symptom-triggered therapy1bRCTs show reduced duration and dose
Thiamine for Wernicke's prevention2aCohort studies, pathophysiological rationale
Acamprosate for relapse prevention1aCochrane review
Naltrexone for relapse prevention1aCOMBINE trial, Cochrane review

11. Patient/Layperson Explanation

What is Alcohol Dependence?

Alcohol dependence, also called alcoholism or alcohol use disorder, is when you find it very difficult to control your drinking even though it is causing problems in your life. Your body becomes used to alcohol, needing more to feel the same effect, and you feel unwell when you try to stop drinking.

What is Alcohol Withdrawal?

When someone who drinks heavily every day suddenly stops or cuts down, their body reacts. This is called withdrawal. Symptoms range from shaking, sweating, and feeling anxious to serious problems like fits (seizures) and confusion. The most severe form, called delirium tremens (DTs), can be life-threatening.

How is it treated?

  1. In hospital or at home: Depending on severity, you may need to be in hospital or can sometimes be treated at home with regular nurse visits.
  2. Vitamins: We give vitamin B1 (thiamine) through a drip to prevent brain damage.
  3. Medication for withdrawal: Tablets (usually chlordiazepoxide) help calm the brain and prevent fits. The dose is gradually reduced over 5-7 days.
  4. Preventing relapse: Medications like acamprosate or naltrexone reduce cravings. Counselling and support groups (like AA) help you stay alcohol-free.

What to expect

  • Withdrawal symptoms usually peak at 24-72 hours and improve over 5-7 days
  • You may feel tired, anxious, and have trouble sleeping for a few weeks
  • Recovery is a long-term process — relapses are common but do not mean failure
  • With the right support, many people achieve lasting recovery

When to seek help

Go to A&E or call 999 if you:

  • Have a seizure (fit)
  • Feel very confused or see/hear things that aren't there
  • Have severe shaking that won't stop
  • Feel your heart beating very fast or irregularly
  • Have a high temperature with severe sweating

12. References

Primary Guidelines

  1. National Institute for Health and Care Excellence. Alcohol-use disorders: diagnosis and management of physical complications (CG100). 2010. NICE CG100
  2. National Institute for Health and Care Excellence. Alcohol-use disorders: diagnosis, assessment and management of harmful drinking and alcohol dependence (CG115). 2011. NICE CG115

Key Trials

  1. Anton RF, et al. Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial. JAMA. 2006;295(17):2003-17. PMID: 16670409
  2. UKATT Research Team. Effectiveness of treatment for alcohol problems: findings of the randomised UK alcohol treatment trial (UKATT). BMJ. 2005;331(7516):541. PMID: 16150764
  3. Amato L, et al. Benzodiazepines for alcohol withdrawal. Cochrane Database Syst Rev. 2010;(3):CD005063. PMID: 20238338

Further Resources

  • Alcoholics Anonymous: alcoholics-anonymous.org.uk
  • Drinkaware: drinkaware.co.uk
  • NHS Alcohol Support: nhs.uk/live-well/alcohol-advice

Last Reviewed: 2025-12-24 | MedVellum Editorial Team


Medical Disclaimer: MedVellum content is for educational purposes and clinical reference. Clinical decisions should account for individual patient circumstances. Always consult appropriate specialists.

Last updated: 2025-12-24

At a Glance

EvidenceHigh
Last Updated2025-12-24
Emergency Protocol

Red Flags

  • Delirium tremens (confusion, seizures, hallucinations)
  • Wernicke's encephalopathy (confusion, ataxia, ophthalmoplegia)
  • Seizures without prior history
  • Hypoglycaemia or electrolyte disturbance
  • Aspiration or respiratory depression

Clinical Pearls

  • **Thiamine Before Glucose**: Always give IV thiamine before any glucose-containing fluids in at-risk patients. Glucose administration can precipitate or worsen Wernicke's encephalopathy.
  • **The 48-72 Hour Window**: Delirium tremens typically develops 48-72 hours after the last drink. Patients who appear stable at 24 hours may still deteriorate — maintain vigilance.
  • **The Concealed Drinker**: Hospital inpatients often underreport alcohol use. Any patient with unexplained tremor, confusion, or agitation 2-3 days into admission should be assessed for AWS.
  • **Red Flags — Urgent treatment required if:**
  • - Seizures (may be first presentation)

Guidelines

  • NICE Guidelines
  • BTS Guidelines
  • RCUK Guidelines